Developer docs
API playgroundTry for free, no card

Search company profiles

Physiogenex

Full company profile

uuid000gd2l

Namestring
Physiogenex
Legal namestring
Physiogenex SAS
Websiteurl
physiogenex.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Physiogenex is a privately-held preclinical contract research organization (CRO) founded in 2003 by Thierry Sulpice (former Sanofi-Aventis scientist) and headquartered near Toulouse, France. The company specializes exclusively in metabolic disease drug development, providing in vivo, ex vivo, and in vitro efficacy testing services to biopharmaceutical, nutraceutical, and agrifood clients worldwide. Its core technology platform rests on 20+ years of proprietary animal model development (mouse, rat, and hamster models of obesity, type 2 diabetes, NASH/MASH, MetALD, fibrosis, diabetic nephropathy, dyslipidemia, and cardiovascular complications), validated gold-standard and radio-tracer-based experimental methodologies (euglycemic clamps, 3H-glucose turnover, nuclear imaging), and an integrated technical platform spanning biochemistry, histology, molecular biology, and imaging.

The company operates from a 5,000m² purpose-built facility opened in July 2019 (1,010m² building with separated laboratories and SPF animal housing), is ISO 9001:2015 certified, and is wholly owned by founders with no external equity backing disclosed. It serves over 100 companies globally, generating project-based professional services revenue through direct B2B sales, scientific consulting engagements, and active presence at major scientific conferences (AASLD, ADA, ASN, Keystone, APASL, WCIRDC). The portfolio includes specialized GLP-1 expertise, a wholly-owned cardiovascular subsidiary (Cardiomedex), and recent product launches including an 8-day IgA nephropathy rat model (October 2024). Customer testimonials indicate a mix of enterprise pharma and mid-market biotech clients across the US, Europe, South America, and Asia-Pacific, with a reported 97.5% customer satisfaction rate in 2023.

Short descriptiontext

Physiogenex is a France-based preclinical CRO specializing in metabolic disease drug development, providing proprietary in vivo, ex vivo, and in vitro animal model services to over 100 biopharmaceutical, nutraceutical, and agrifood companies worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLabège, France
HQ citystring
Labège
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, metabolic disease research, animal model development, drug efficacy testing, in vivo pharmacology
Industry1 code
PRIMARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Preclinical CRO Services
TypeProfessional Services
Description

Core revenue stream from providing preclinical in vivo and ex vivo CRO services to biopharmaceutical, nutraceutical, and agrifood companies. Services include efficacy studies, pharmacology studies, drug activity and mechanism of action studies, and evaluation of adverse effects across metabolic disorder indications. Revenue is project-based, typically structured as one-time study contracts with consulting add-ons.

physiogenex.com
2CRO Consulting Services
TypeProfessional Services
Description

Customized consulting services providing literature searches, data analysis, and drug development recommendations. Includes continuous interaction with client phone conferences, on-site face-to-face meetings, and complete consulting reports with scientific references. Offered as an add-on to CRO services.

physiogenex.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Physiogenex provides preclinical in vivo, ex vivo, and in vitro contract research services for metabolic disorders using proprietary and gold-standard animal models (mouse, rat, hamster) covering obesity, type 2 diabetes, NASH/MASH, fibrosis, diabetic nephropathy, dyslipidemia, atherosclerosis, and cardiovascular complications. The offering spans efficacy studies, gold-standard radio-tracer-based experiments, biochemical and histological analyses, biological sample supply, and expert consulting tailored to biopharmaceutical, nutraceutical, and agrifood clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 97.5% customer satisfaction / success rate in 2023
+3 more records
Product overview1 text field

Physiogenex is a preclinical contract research organization (CRO) providing a unified portfolio of in vivo, ex vivo, and in vitro drug efficacy testing services for metabolic disorders. The core offering is built around proprietary animal models (mouse, rat, and hamster) of obesity, type 2 diabetes, NASH/MASH, fibrosis, diabetic nephropathy, neuropathy, dyslipidemia, and cardiovascular complications. These models are supported by integrated services including ex vivo metabolic assays (isolated adipocytes and muscle), biochemical and histology analysis, a biological samples library, and expert consulting. Therapeutic area services span NASH/MASH/MetALD, obesity/diabetes, diabetic nephropathy/CKD, dyslipidemia/atherosclerosis, fibrosis, immunometabolism, diabetic neuropathy, nutraceuticals, and COVID-19 metabolic comorbidities. The platform is augmented by specialized GLP-1 expertise and radio-tracer-based experiments for mechanistic studies.

Product and service17 records
1In vivo metabolic studies
CategoryPreclinical CRO capability
Description

Preclinical in vivo studies using validated animal models to demonstrate drug efficacy in metabolic disorders, including glucose homeostasis tests (GTT, ITT, euglycemic hyperinsulinemic clamp), lipid metabolism studies, heart metabolism assessments, and in vivo lipogenesis measurements, offered to pharmaceutical, biotech, nutraceutical, and agrifood clients.

2Ex vivo metabolic assays
CategoryPreclinical CRO capability
Description

Ex vivo screening assays using isolated muscles or adipocytes from in-house animal models, including lipolysis on isolated adipocytes, glucose uptake on isolated adipocytes, muscle glucose uptake, and muscle free fatty acid oxidation for medium-throughput screening.

3Biochemical assays and histology analysis
CategoryPreclinical CRO capability
Description

Comprehensive biochemical assays (colorimetric, ELISA, multiplex, Western Blot) and histology analysis (H&E, Sirius Red, Masson Trichrome, ORO, PAS, immunohistochemistry, NAS scoring) for full characterization of drug candidates.

4Biological samples library
CategoryPreclinical CRO capability
Description

Supply of frozen plasma/organ samples and formalin-fixed paraffin-embedded liver and kidney samples from benchmarked mouse, rat, and hamster models for initial drug target validation.

5CRO consulting services
CategoryPreclinical CRO capability
Description

Expert consulting services providing customized literature searches, analysis of available data on drug targets, and recommendations for successful drug development, with continuous interaction via phone conferences and face-to-face meetings.

6NASH/MASH/MetALD preclinical CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services for evaluating drugs targeting NASH/MASH and liver fibrosis, including in vitro hepatocyte models, rapid 1-8 week animal models, diet-induced obese NASH/MASH hamster models, and MetALD models with human-like lipoprotein profiles.

7Obesity, insulin resistance, and type 2 diabetes preclinical CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services for obesity, insulin resistance, and type 2 diabetes using nutritional and genetic animal models including diet-induced obese mouse, rat, and hamster models, ob/ob and db/db mice, Zucker diabetic fatty rats, and STZ-induced diabetes models.

8Diabetic nephropathy and CKD preclinical CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services for diabetic nephropathy and chronic kidney disease using db/db mouse on high protein diet and uni-nephrectomized/salt-supplemented SDT fatty rat models, with GFR measurement using Medibeacon devices.

9Dyslipidaemia and atherosclerosis preclinical CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services for dyslipidaemia and atherosclerosis using validated hamster and mouse models, including lipoprotein kinetics, macrophage-to-feces reverse cholesterol transport, and VCAM-1 nuclear imaging.

10GLP-1 expertise services
CategoryTherapeutic area CRO service
Description

Specialized GLP-1 and incretin therapy development services with over 15 years of experience, including acute effects testing, chronic weight loss studies, beta-cell preservation, NASH/MASH modulation, and diabetic nephropathy assessment using validated models.

11Diabetic neuropathy preclinical CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services for diabetic neuropathy using DIO-STZ mouse model developing diabetic nephropathy and neuropathy, with Von Frey mechanical sensitivity assays, gastric emptying assays, and GFR measurements.

12Fibrosis preclinical CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services for fibrosis targeting liver, kidney, and lung fibrosis using CCl4 mouse and rat models, thioacetamide rat model, UUO mouse model, and bleomycin-induced IPF DIO mouse model.

13Immunometabolism preclinical CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services evaluating drugs on immune system role in low-grade inflammation across metabolic tissues, using FACS analysis for innate and adaptive immune cell characterization, and DSS-induced colitis mouse model.

14Nutraceuticals preclinical studies
CategoryTherapeutic area CRO service
Description

Preclinical evaluation of nutraceuticals using benchmarked diet-induced obese mouse, rat, and hamster models, benchmarked with anti-obesity drugs and vegetal extracts, with optional gut microbiota analysis via Vaiomer partnership.

15COVID-19 CRO services
CategoryTherapeutic area CRO service
Description

Preclinical CRO services using free-choice diet-induced obese NASH/MASH hamster infected with SARS-CoV-2 as a metabolic comorbidities model of COVID-19, developed in collaboration with Institut Pasteur de Lille.

16In vitro and ex vivo assays
CategoryPreclinical CRO capability
Description

In vitro and ex vivo services including lipolysis and glucose uptake on human and rodent adipocytes, glucose uptake on isolated muscle, HepaRG hepatocyte steatosis screening, and 3D NASH liver spheroid models for drug efficacy testing.

17IgA nephropathy (IgAN) rat model
CategoryTherapeutic area CRO service
Description

Novel rat model of IgA nephropathy (IgAN) for rapidly evaluating drug efficacy targeting IgAN in only 8 days. Readouts include Glomerular Filtration Rate (GFR), urine parameters (KIM-1, ACR), and kidney histology quantification (mesangial expansion, podocyte effacement) via Nipoka and Aiosyn partners.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Vaiomer
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Launch of the TRANSBIOTIC project: a 3-year collaborative research project supported by Région Occitanie to transplant mice with human fecal microbiome from patients with metabolic and inflammatory diseases. Vaiomer provides in-depth bacterial microbiome analysis through its expertise in blood and tissue microbiome exploration, while Physiogenex provides expertise in phenotyping animal models of metabolic diseases. The partnership addresses growing demand for microbiome-based animal models in drug development.

physiogenex.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration with Institut Pasteur de Lille to develop a unique metabolic comorbidities COVID-19 model: the free-choice diet-induced obese NASH/MASH hamster infected with SARS-CoV-2. This model addresses the demonstrated link between obesity, type 2 diabetes, NASH, and severe COVID-19 outcomes in humans.

3CLEA Japan Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Strategic partnership since 2016 for the development and co-commercialization of the SDT fatty rat as a model of Type 2 diabetic nephropathy, retinopathy, and cardiometabolic complications. CLEA Japan Inc. produces SPF animals and provides CRO services to Physiogenex, with collaborative work presented at ASN Kidney Week, ISN, and ARVO conferences.

physiogenex.com
Strategic tierCore SubsidiaryTypeStrategic or Co-development Partner
Description

Cardiomedex is a subsidiary company of Physiogenex sharing the same management and facilities near Toulouse. It specializes in cardiovascular diseases, onco-cardiology, and neurocardiology preclinical CRO services, evaluating cardiovascular effects of drug candidates including myocardial infarction, cardiac arrhythmia, cardiac hypertrophy, heart failure, hypertension, and cardiotoxicity. Cardiomedex services are integrated with Physiogenex's models to provide comprehensive cardiometabolic disorder evaluation. Co-developed innovative in vivo models of cardiometabolism with shared facilities.

5Janvier Group
Strategic tierPreferred VendorTypeChannel Partner/ Reseller/ Distributor
Description

Janvier Group is a major supplier of well-characterized in vitro, in vivo, and custom-created animal models to Physiogenex. With over 3500 clients worldwide and 600+ dedicated experts, Janvier Group provides validated animal models and related services that complement Physiogenex's service offering.

physiogenex.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Expert supplier of experimental rodents providing best quality bioservices to researchers. Provides experimental rodent supply and bioservices to support Physiogenex's preclinical studies.

Strategic tierPreferred VendorTypeTechnology or Integration
Description

Provides FITC-sinistrin devices for non-invasive, repeated measurement of Glomerular Filtration Rate (GFR) in preclinical kidney function studies. Used in Physiogenex's diabetic nephropathy and CKD models for sensitive, less invasive kidney function tracking during drug treatment.

8Pr. Rémy Burcelin (INSERM/I2MC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Chairman of Physiogenex's Scientific Advisory Board and founder. Research Director at INSERM (I2MC 1048) specializing in molecular bases of glycaemic control, insulin resistance, gut-brain axis, microbiota, and cardiometabolic diseases. Has published 120+ peer-reviewed papers and founded/contributed to 7 biotech companies. Provides scientific expertise and consulting for GLP-1/incretin therapies and metabolic disease drug development.

physiogenex.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gubra is a Danish preclinical CRO specializing in metabolic diseases and fibro-inflammation with proprietary obesity, diabetes, and NASH/MASH models, closely paralleling Physiogenex's core offerings. Both companies serve biopharma clients with in vivo efficacy studies and are direct competitors in the metabolic CRO niche.

TypeDirect peer
Description

Crown Bioscience (JSR Life Sciences) is a global preclinical CRO with extensive oncology and metabolic disease models including obesity, diabetes, and NASH offerings. It is a direct competitor serving similar biopharma clients with in vivo efficacy testing in metabolic indications.

TypeBroad incumbent
Description

Charles River Laboratories is a major global CRO offering comprehensive preclinical services including metabolic disease models, safety assessment, and discovery services. As a broad incumbent, it competes with Physiogenex for metabolic preclinical contracts while serving a much wider therapeutic portfolio.

TypeBroad incumbent
Description

Labcorp Drug Development (formerly Covance) provides extensive preclinical and clinical CRO services including metabolic disease capabilities. It is a broad incumbent offering one-stop-shop preclinical-to-clinical services that competes with Physiogenex for biopharma study contracts.

TypeBroad incumbent
Description

Eurofins Scientific is a large international group offering bioanalytical, preclinical, and CRO services through subsidiaries. Its central laboratory and preclinical divisions compete with Physiogenex in metabolic disease research support for global pharma clients.

TypeBroad incumbent
Description

Inotiv is a US-based contract research organization providing preclinical research services and research models across multiple therapeutic areas including metabolic diseases. It serves as a broad incumbent competitor with model production and contract study capabilities.

TypeBroad incumbent
Description

Wuxi AppTec is a leading global CRO/CDMO offering preclinical, clinical, and manufacturing services with extensive capabilities in metabolic and other therapeutic areas. As a broad incumbent with significant scale, it competes for large pharma preclinical contracts.

TypeEmerging player
Description

Taconic Biosciences is a supplier of genetically engineered rodent models and related preclinical services for metabolic and other diseases. While primarily a model supplier, its service offering overlaps with Physiogenex's biological samples library and certain in vivo capabilities.

TypeRegional player
Description

ChemPartner (Shanghai) is a China-based preclinical CRO providing in vivo pharmacology services across metabolic, oncology, and CNS indications. It serves as an Asia-focused competitor for biopharma clients seeking metabolic disease preclinical studies.

TypeOthers
Description

SPARC is an India-based pharmaceutical R&D organization with significant preclinical capabilities in metabolic and inflammatory diseases. While not a pure CRO, it occasionally partners with and competes against preclinical CROs for outsourced metabolic disease studies in Asia.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Physiogenex

Preclinical Contract Research Servicesphysiogenex.com

Physiogenex is a France-based preclinical CRO specializing in metabolic disease drug development, providing proprietary in vivo, ex vivo, and in vitro animal model services to over 100 biopharmaceutical, nutraceutical, and agrifood companies worldwide.

What Physiogenex does

Physiogenex is a privately-held preclinical contract research organization (CRO) founded in 2003 by Thierry Sulpice (former Sanofi-Aventis scientist) and headquartered near Toulouse, France. The company specializes exclusively in metabolic disease drug development, providing in vivo, ex vivo, and in vitro efficacy testing services to biopharmaceutical, nutraceutical, and agrifood clients worldwide. Its core technology platform rests on 20+ years of proprietary animal model development (mouse, rat, and hamster models of obesity, type 2 diabetes, NASH/MASH, MetALD, fibrosis, diabetic nephropathy, dyslipidemia, and cardiovascular complications), validated gold-standard and radio-tracer-based experimental methodologies (euglycemic clamps, 3H-glucose turnover, nuclear imaging), and an integrated technical platform spanning biochemistry, histology, molecular biology, and imaging.

The company operates from a 5,000m² purpose-built facility opened in July 2019 (1,010m² building with separated laboratories and SPF animal housing), is ISO 9001:2015 certified, and is wholly owned by founders with no external equity backing disclosed. It serves over 100 companies globally, generating project-based professional services revenue through direct B2B sales, scientific consulting engagements, and active presence at major scientific conferences (AASLD, ADA, ASN, Keystone, APASL, WCIRDC). The portfolio includes specialized GLP-1 expertise, a wholly-owned cardiovascular subsidiary (Cardiomedex), and recent product launches including an 8-day IgA nephropathy rat model (October 2024). Customer testimonials indicate a mix of enterprise pharma and mid-market biotech clients across the US, Europe, South America, and Asia-Pacific, with a reported 97.5% customer satisfaction rate in 2023.

Physiogenex firmographics

Firmographics
Name
Physiogenex
Legal name
Physiogenex SAS
Website
https://physiogenex.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Physiogenex is a France-based preclinical CRO specializing in metabolic disease drug development, providing proprietary in vivo, ex vivo, and in vitro animal model services to over 100 biopharmaceutical, nutraceutical, and agrifood companies worldwide.
Ownership category
akta.pro rank

Physiogenex industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Preclinical CRO services
  • Metabolic disease research
  • Animal model development
  • Drug efficacy testing
  • In vivo pharmacology

Where Physiogenex is headquartered

Location

Headquarters

HQ city
Labège
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Physiogenex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Preclinical CRO Services: Core revenue stream from providing preclinical in vivo and ex vivo CRO services to biopharmaceutical, nutraceutical, and agrifood companies. Services include efficacy studies, pharmacology studies, drug activity and mechanism of action studies, and evaluation of adverse effects across metabolic disorder indications. Revenue is project-based, typically structured as one-time study contracts with consulting add-ons.
  2. CRO Consulting Services: Customized consulting services providing literature searches, data analysis, and drug development recommendations. Includes continuous interaction with client phone conferences, on-site face-to-face meetings, and complete consulting reports with scientific references. Offered as an add-on to CRO services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Physiogenex product offering

Product offering

Core offering

Physiogenex provides preclinical in vivo, ex vivo, and in vitro contract research services for metabolic disorders using proprietary and gold-standard animal models (mouse, rat, hamster) covering obesity, type 2 diabetes, NASH/MASH, fibrosis, diabetic nephropathy, dyslipidemia, atherosclerosis, and cardiovascular complications. The offering spans efficacy studies, gold-standard radio-tracer-based experiments, biochemical and histological analyses, biological sample supply, and expert consulting tailored to biopharmaceutical, nutraceutical, and agrifood clients.

Product overview

Physiogenex is a preclinical contract research organization (CRO) providing a unified portfolio of in vivo, ex vivo, and in vitro drug efficacy testing services for metabolic disorders. The core offering is built around proprietary animal models (mouse, rat, and hamster) of obesity, type 2 diabetes, NASH/MASH, fibrosis, diabetic nephropathy, neuropathy, dyslipidemia, and cardiovascular complications. These models are supported by integrated services including ex vivo metabolic assays (isolated adipocytes and muscle), biochemical and histology analysis, a biological samples library, and expert consulting. Therapeutic area services span NASH/MASH/MetALD, obesity/diabetes, diabetic nephropathy/CKD, dyslipidemia/atherosclerosis, fibrosis, immunometabolism, diabetic neuropathy, nutraceuticals, and COVID-19 metabolic comorbidities. The platform is augmented by specialized GLP-1 expertise and radio-tracer-based experiments for mechanistic studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • In vivo metabolic studies Preclinical in vivo studies using validated animal models to demonstrate drug efficacy in metabolic disorders, including glucose homeostasis tests (GTT, ITT, euglycemic hyperinsulinemic clamp), lipid metabolism studies, heart metabolism assessments, and in vivo lipogenesis measurements, offered to pharmaceutical, biotech, nutraceutical, and agrifood clients.
  • Ex vivo metabolic assays Ex vivo screening assays using isolated muscles or adipocytes from in-house animal models, including lipolysis on isolated adipocytes, glucose uptake on isolated adipocytes, muscle glucose uptake, and muscle free fatty acid oxidation for medium-throughput screening.
  • Biochemical assays and histology analysis Comprehensive biochemical assays (colorimetric, ELISA, multiplex, Western Blot) and histology analysis (H&E, Sirius Red, Masson Trichrome, ORO, PAS, immunohistochemistry, NAS scoring) for full characterization of drug candidates.
  • Biological samples library Supply of frozen plasma/organ samples and formalin-fixed paraffin-embedded liver and kidney samples from benchmarked mouse, rat, and hamster models for initial drug target validation.
  • CRO consulting services Expert consulting services providing customized literature searches, analysis of available data on drug targets, and recommendations for successful drug development, with continuous interaction via phone conferences and face-to-face meetings.
  • NASH/MASH/MetALD preclinical CRO services Preclinical CRO services for evaluating drugs targeting NASH/MASH and liver fibrosis, including in vitro hepatocyte models, rapid 1-8 week animal models, diet-induced obese NASH/MASH hamster models, and MetALD models with human-like lipoprotein profiles.
  • Obesity, insulin resistance, and type 2 diabetes preclinical CRO services Preclinical CRO services for obesity, insulin resistance, and type 2 diabetes using nutritional and genetic animal models including diet-induced obese mouse, rat, and hamster models, ob/ob and db/db mice, Zucker diabetic fatty rats, and STZ-induced diabetes models.
  • Diabetic nephropathy and CKD preclinical CRO services Preclinical CRO services for diabetic nephropathy and chronic kidney disease using db/db mouse on high protein diet and uni-nephrectomized/salt-supplemented SDT fatty rat models, with GFR measurement using Medibeacon devices.
  • Dyslipidaemia and atherosclerosis preclinical CRO services Preclinical CRO services for dyslipidaemia and atherosclerosis using validated hamster and mouse models, including lipoprotein kinetics, macrophage-to-feces reverse cholesterol transport, and VCAM-1 nuclear imaging.
  • GLP-1 expertise services Specialized GLP-1 and incretin therapy development services with over 15 years of experience, including acute effects testing, chronic weight loss studies, beta-cell preservation, NASH/MASH modulation, and diabetic nephropathy assessment using validated models.
  • Diabetic neuropathy preclinical CRO services Preclinical CRO services for diabetic neuropathy using DIO-STZ mouse model developing diabetic nephropathy and neuropathy, with Von Frey mechanical sensitivity assays, gastric emptying assays, and GFR measurements.
  • Fibrosis preclinical CRO services Preclinical CRO services for fibrosis targeting liver, kidney, and lung fibrosis using CCl4 mouse and rat models, thioacetamide rat model, UUO mouse model, and bleomycin-induced IPF DIO mouse model.
  • Immunometabolism preclinical CRO services Preclinical CRO services evaluating drugs on immune system role in low-grade inflammation across metabolic tissues, using FACS analysis for innate and adaptive immune cell characterization, and DSS-induced colitis mouse model.
  • Nutraceuticals preclinical studies Preclinical evaluation of nutraceuticals using benchmarked diet-induced obese mouse, rat, and hamster models, benchmarked with anti-obesity drugs and vegetal extracts, with optional gut microbiota analysis via Vaiomer partnership.
  • COVID-19 CRO services Preclinical CRO services using free-choice diet-induced obese NASH/MASH hamster infected with SARS-CoV-2 as a metabolic comorbidities model of COVID-19, developed in collaboration with Institut Pasteur de Lille.
  • In vitro and ex vivo assays In vitro and ex vivo services including lipolysis and glucose uptake on human and rodent adipocytes, glucose uptake on isolated muscle, HepaRG hepatocyte steatosis screening, and 3D NASH liver spheroid models for drug efficacy testing.
  • IgA nephropathy (IgAN) rat model Novel rat model of IgA nephropathy (IgAN) for rapidly evaluating drug efficacy targeting IgAN in only 8 days. Readouts include Glomerular Filtration Rate (GFR), urine parameters (KIM-1, ACR), and kidney histology quantification (mesangial expansion, podocyte effacement) via Nipoka and Aiosyn partners.

Quantifiable outcome

  • 97.5% customer satisfaction / success rate in 2023
  • +3 more outcomes

Companies that use Physiogenex

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Physiogenex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

Physiogenex partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered strategic, core, core subsidiary, preferred vendor and minor.

  • VaiomerstrategicStrategic or Co-development Partner · 1 January 2023Launch of the TRANSBIOTIC project: a 3-year collaborative research project supported by Région Occitanie to transplant mice with human fecal microbiome from patients with metabolic and inflammatory diseases. Vaiomer provides in-depth bacterial microbiome analysis through its expertise in blood and tissue microbiome exploration, while Physiogenex provides expertise in phenotyping animal models of metabolic diseases. The partnership addresses growing demand for microbiome-based animal models in drug development.
  • Institut Pasteur de LillestrategicStrategic or Co-development Partner · 1 January 2021Collaboration with Institut Pasteur de Lille to develop a unique metabolic comorbidities COVID-19 model: the free-choice diet-induced obese NASH/MASH hamster infected with SARS-CoV-2. This model addresses the demonstrated link between obesity, type 2 diabetes, NASH, and severe COVID-19 outcomes in humans.
  • CLEA Japan Inc.coreStrategic or Co-development Partner · 1 January 2016Strategic partnership since 2016 for the development and co-commercialization of the SDT fatty rat as a model of Type 2 diabetic nephropathy, retinopathy, and cardiometabolic complications. CLEA Japan Inc. produces SPF animals and provides CRO services to Physiogenex, with collaborative work presented at ASN Kidney Week, ISN, and ARVO conferences.
  • Cardiomedexcore subsidiaryStrategic or Co-development PartnerCardiomedex is a subsidiary company of Physiogenex sharing the same management and facilities near Toulouse. It specializes in cardiovascular diseases, onco-cardiology, and neurocardiology preclinical CRO services, evaluating cardiovascular effects of drug candidates including myocardial infarction, cardiac arrhythmia, cardiac hypertrophy, heart failure, hypertension, and cardiotoxicity. Cardiomedex services are integrated with Physiogenex's models to provide comprehensive cardiometabolic disorder evaluation. Co-developed innovative in vivo models of cardiometabolism with shared facilities.
  • Janvier Grouppreferred vendorChannel Partner/ Reseller/ DistributorJanvier Group is a major supplier of well-characterized in vitro, in vivo, and custom-created animal models to Physiogenex. With over 3500 clients worldwide and 600+ dedicated experts, Janvier Group provides validated animal models and related services that complement Physiogenex's service offering.
  • Central Lab. Animal Inc.minorChannel Partner/ Reseller/ DistributorExpert supplier of experimental rodents providing best quality bioservices to researchers. Provides experimental rodent supply and bioservices to support Physiogenex's preclinical studies.
  • Medibeaconpreferred vendorTechnology or IntegrationProvides FITC-sinistrin devices for non-invasive, repeated measurement of Glomerular Filtration Rate (GFR) in preclinical kidney function studies. Used in Physiogenex's diabetic nephropathy and CKD models for sensitive, less invasive kidney function tracking during drug treatment.
  • Pr. Rémy Burcelin (INSERM/I2MC)coreStrategic or Co-development PartnerChairman of Physiogenex's Scientific Advisory Board and founder. Research Director at INSERM (I2MC 1048) specializing in molecular bases of glycaemic control, insulin resistance, gut-brain axis, microbiota, and cardiometabolic diseases. Has published 120+ peer-reviewed papers and founded/contributed to 7 biotech companies. Provides scientific expertise and consulting for GLP-1/incretin therapies and metabolic disease drug development.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Physiogenex competitors and assessment

Company assessment

Direct peers

  • Gubra: Gubra is a Danish preclinical CRO specializing in metabolic diseases and fibro-inflammation with proprietary obesity, diabetes, and NASH/MASH models, closely paralleling Physiogenex's core offerings. Both companies serve biopharma clients with in vivo efficacy studies and are direct competitors in the metabolic CRO niche.
  • Crown Bioscience: Crown Bioscience (JSR Life Sciences) is a global preclinical CRO with extensive oncology and metabolic disease models including obesity, diabetes, and NASH offerings. It is a direct competitor serving similar biopharma clients with in vivo efficacy testing in metabolic indications.

Broad incumbents

  • Charles River Laboratories: Charles River Laboratories is a major global CRO offering comprehensive preclinical services including metabolic disease models, safety assessment, and discovery services. As a broad incumbent, it competes with Physiogenex for metabolic preclinical contracts while serving a much wider therapeutic portfolio.
  • Labcorp Drug Development: Labcorp Drug Development (formerly Covance) provides extensive preclinical and clinical CRO services including metabolic disease capabilities. It is a broad incumbent offering one-stop-shop preclinical-to-clinical services that competes with Physiogenex for biopharma study contracts.
  • Eurofins Scientific: Eurofins Scientific is a large international group offering bioanalytical, preclinical, and CRO services through subsidiaries. Its central laboratory and preclinical divisions compete with Physiogenex in metabolic disease research support for global pharma clients.
  • Inotiv: Inotiv is a US-based contract research organization providing preclinical research services and research models across multiple therapeutic areas including metabolic diseases. It serves as a broad incumbent competitor with model production and contract study capabilities.
  • Wuxi AppTec: Wuxi AppTec is a leading global CRO/CDMO offering preclinical, clinical, and manufacturing services with extensive capabilities in metabolic and other therapeutic areas. As a broad incumbent with significant scale, it competes for large pharma preclinical contracts.

Emerging players

  • Taconic Biosciences: Taconic Biosciences is a supplier of genetically engineered rodent models and related preclinical services for metabolic and other diseases. While primarily a model supplier, its service offering overlaps with Physiogenex's biological samples library and certain in vivo capabilities.

Regional players

  • ChemPartner: ChemPartner (Shanghai) is a China-based preclinical CRO providing in vivo pharmacology services across metabolic, oncology, and CNS indications. It serves as an Asia-focused competitor for biopharma clients seeking metabolic disease preclinical studies.

Others

  • Sun Pharma Advanced Research Company (SPARC): SPARC is an India-based pharmaceutical R&D organization with significant preclinical capabilities in metabolic and inflammatory diseases. While not a pure CRO, it occasionally partners with and competes against preclinical CROs for outsourced metabolic disease studies in Asia.

Market position

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Physiogenex social profiles

Digital presence

Physiogenex compliance and trust

Trust signal

Compliance1 record

Physiogenex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Physiogenex leadership team

Management profile

Number of profiles

Profiles9 records

Physiogenex subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Physiogenex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Physiogenex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Physiogenex

What does Physiogenex do?

Physiogenex provides preclinical in vivo, ex vivo, and in vitro contract research services for metabolic disorders using proprietary and gold-standard animal models (mouse, rat, hamster) covering obesity, type 2 diabetes, NASH/MASH, fibrosis, diabetic nephropathy, dyslipidemia, atherosclerosis, and cardiovascular complications. The offering spans efficacy studies, gold-standard radio-tracer-based experiments, biochemical and histological analyses, biological sample supply, and expert consulting tailored to biopharmaceutical, nutraceutical, and agrifood clients.

Is Physiogenex a public or private company?

Physiogenex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Physiogenex founded?

Physiogenex was founded in 2003. It employs 11 to 50 people.

Where is Physiogenex based?

Physiogenex is headquartered in Labège, France, in the Europe region.

How does Physiogenex make money?

Two revenue lines are on record. Preclinical CRO Services are the primary driver. The others are CRO Consulting Services.

Who are Physiogenex's main competitors?

Direct peers on record are Gubra and Crown Bioscience. Broad incumbents are Charles River Laboratories, Labcorp Drug Development, Eurofins Scientific, Inotiv and Wuxi AppTec. Taconic Biosciences is listed as an emerging player. ChemPartner is listed as a regional player. Sun Pharma Advanced Research Company (SPARC) is listed as an others.

Does Physiogenex have an API?

No public API is recorded for Physiogenex.

What industry is Physiogenex in?

Physiogenex's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAFAA, In Vivo Pharmacology (Efficacy/PD Models). Its NAICS code is 541715 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales